In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bridging The Gap Between Sell- And Buy- Sides In Biopharma Business Development

Executive Summary

The biotech financing drought, combined with increasing externalization of pharma R&D, should be creating an ideal climate for successful dealmaking. Yet executing partnerships between biopharma sellers and buyers remains incredibly challenging. Locust Walk Partners surveyed senior business development executives to find the keys to executing mutually satisfying deals.
Advertisement

Related Content

Your First Drug's Approved and Launched...Now What?
Your First Drug's Approved and Launched...Now What?
Forma To Play To Its Strengths WIth Genentech Deal
Daiichi's Handsome Buyout Price Validates Plexxikon's Business Model
Daiichi's Handsome Buyout Price Validates Plexxikon's Business Model
Reimbursement: The New Biopharma Investment Hurdle
Reimbursement: The New Biopharma Investment Hurdle

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003697

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel